THE UK’s Health Research Authority (HRA) has approved the country’s first clinical study using cannabis flower for the treatment of
CELADON Pharmaceuticals successfully listed on the Alternative Investments Market (AIM) this week, making it the first British company to join
SUMMERWAY Capital’s (LON: SWC) £80m reverse takeover of one of the UK’s few licenced high-THC cannabis growers has seen it relaunch its shares on the London Stock Exchange (LSE) in order to fund its new acquisition.
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
